Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone510-848-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.20 million
Profitability
Miscellaneous
Employees249
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions
What is Dynavax Technologies' stock symbol?
Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."
How were Dynavax Technologies' earnings last quarter?
Dynavax Technologies Co. (NASDAQ:DVAX) announced its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.03. The biopharmaceutical company had revenue of $8.30 million for the quarter, compared to analyst estimates of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The business's revenue for the quarter was up 564.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.63) EPS. View Dynavax Technologies' Earnings History.
When is Dynavax Technologies' next earnings date?
What price target have analysts set for DVAX?
4 brokerages have issued 1-year price targets for Dynavax Technologies' shares. Their forecasts range from $13.00 to $30.00. On average, they expect Dynavax Technologies' stock price to reach $21.00 in the next year. This suggests a possible upside of 394.1% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.
What is the consensus analysts' recommendation for Dynavax Technologies?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.
Has Dynavax Technologies been receiving favorable news coverage?
News headlines about DVAX stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Dynavax Technologies.
Who are some of Dynavax Technologies' key competitors?
Some companies that are related to Dynavax Technologies include Innoviva (INVA), Esperion Therapeutics (ESPR), ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Odonate Therapeutics (ODT), AnaptysBio (ANAB), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), ANI Pharmaceuticals (ANIP) and Phibro Animal Health (PAHC).
What other stocks do shareholders of Dynavax Technologies own?
Who are Dynavax Technologies' key executives?
Dynavax Technologies' management team includes the folowing people:
- Mr. Eddie Gray, CEO & Director (Age 60)
- Dr. Dennis A. Carson Ph.D., M.D., Co-Founder, Director & Member of Scientific Advisory Board (Age 72)
- Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 67)
- Mr. David F. Novack, Sr. VP of Operations & Quality (Age 57)
- Dr. Robert L. Coffman, Chief Scientific Officer & Sr. VP (Age 72)
Who are Dynavax Technologies' major shareholders?
Dynavax Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (0.02%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.
Which major investors are buying Dynavax Technologies stock?
How do I buy shares of Dynavax Technologies?
Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Dynavax Technologies' stock price today?
One share of DVAX stock can currently be purchased for approximately $4.25.
How big of a company is Dynavax Technologies?
Dynavax Technologies has a market capitalization of $276.91 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.
What is Dynavax Technologies' official website?
How can I contact Dynavax Technologies?
Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]
MarketBeat Community Rating for Dynavax Technologies (NASDAQ DVAX)
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
